Professor of Radiation Oncology, University Wisc
Radiation Oncology
Dr. Paul M. Harari, MD
|
|
Give Review
Dr. Paul M. Harari practices Radiation Oncology. He graduated from University of Virginia School of Medicine. He received awards:"America's Top Doctors" and "America's Top Doctors for Cancer". Paul Harari is also published. He has 99 publications published. The lastest publication: "Improving dose homogeneity in routine head and neck radiotherapy with custom 3-D compensation.' He accepts Medicare payments and is listed with Medicare.gov.
Publications
- Pan-HER Inhibitor Augments Radiation Response in Human Lung and Head and Neck Cancer Models.
- Metabolic Tumor Volume as a Prognostic Imaging-Based Biomarker for Head-and-Neck Cancer: Pilot Results From Radiation Therapy Oncology Group Protocol 0522.
- Phase 1 Trial of Bevacizumab With Concurrent Chemoradiation Therapy for Squamous Cell Carcinoma of the Head and Neck With Exploratory Functional Imaging of Tumor Hypox...
- Patient and tumor characteristics predictive of primary parotid gland malignancy: A 20-year experience at the University of Wisconsin.
- Xenograft assessment of predictive biomarkers for standard head and neck cancer therapies.
- Selective omission of level v nodal coverage for patients with oropharynx cancer: Clinical validation of intensity modulated radiotherapy experience and dosimetric sig...
- Impact of Node Negative Target Volume Delineation on Contralateral Parotid Gland Dose Sparing Using IMRT in Head and Neck Cancer.
- Interaction of Radiation Therapy With Molecular Targeted Agents.
- Postoperative Chemoradiotherapy and Cetuximab for High-Risk Squamous Cell Carcinoma of the Head and Neck: Radiation Therapy Oncology Group RTOG-0234.
- Sym004, a Novel Anti-EGFR Antibody Mixture, Augments Radiation Response in Human Lung and Head and Neck Cancers.
- Is radiation dose reduction the right answer for HPV-positive head and neck cancer?
- Risk of cerebrovascular events in elderly patients after radiation therapy versus surgery for early-stage glottic cancer.
- Enhanced Radiation Sensitivity in HPV-Positive Head and Neck Cancer.
- Increased local failure risk with prolonged radiation treatment time in head and neck cancer treated with concurrent chemotherapy.
- Acute Hematologic and Mucosal Toxicities in Head and Neck Cancer Patients Undergoing Chemoradiotherapy: A Comparison of 3D-CRT, IMRT, and Helical Tomotherapy.
- Cetuximab and bevacizumab: preclinical data and phase II trial in recurrent or metastatic squamous cell carcinoma of the head and neck.
- Head and neck carcinoma in the United States: first comprehensive report of the Longitudinal Oncology Registry of Head and Neck Carcinoma (LORHAN).
- Dual targeting of EGFR and HER3 with MEHD7945A overcomes acquired resistance to EGFR inhibitors and radiation.
- p53 Modulates Acquired Resistance to EGFR Inhibitors and Radiation.
- Longitudinal oncology registry of head and neck carcinoma (LORHAN): analysis of chemoradiation treatment approaches in the United States.
- Robotics in head and neck cancer: future opportunities.
- Head and neck squamous cell carcinoma from an unknown primary site.
- Augmentation of radiation response by motesanib, a multikinase inhibitor that targets vascular endothelial growth factor receptors.
- Emphasizing conformal avoidance versus target definition for IMRT planning in head-and-neck cancer.
- Comprehensive IMRT plus weekly cisplatin for advanced head and neck cancer: the University of Wisconsin experience.
- Therapeutic selective neck dissection outcomes.
- Multi-institutional trial of accelerated hypofractionated intensity-modulated radiation therapy for early-stage oropharyngeal cancer (RTOG 00-22).
- Regulation of heparin-binding EGF-like growth factor by miR-212 and acquired cetuximab-resistance in head and neck squamous cell carcinoma.
- Epidermal growth factor receptor cooperates with Src family kinases in acquired resistance to cetuximab.
- A comprehensive assessment by tumor site of patient setup using daily MVCT imaging from more than 3,800 helical tomotherapy treatments.
- Establishment and characterization of a model of acquired resistance to epidermal growth factor receptor targeting agents in human cancer cells.
- Hidradenomas and a hidradenocarcinoma of the scalp managed using Mohs micrographic surgery and a multidisciplinary approach: case reports and review of the literature.
- Molecular target approaches in head and neck cancer: epidermal growth factor receptor and beyond.
- Augmentation of radiation response by panitumumab in models of upper aerodigestive tract cancer.
- Tumor volume as a prognostic factor in oropharyngeal squamous cell carcinoma treated with primary radiotherapy.
- Beware the swing and a miss: baseball precautions for conformal radiotherapy.
- EGFR inhibitors for the treatment of squamous cell carcinoma of the head and neck.
- Clinical application of EGFR inhibitors in head and neck squamous cell cancer.
- Radiation oncology advances: an introduction.
- Megavoltage computed tomography: an emerging tool for image-guided radiotherapy.
- Are we influencing outcome in oropharynx cancer with intensity-modulated radiotherapy? An inter-era comparison.
- Biology of interactions: antiepidermal growth factor receptor agents.
- Quality of life in head and neck cancer patients after treatment with high-dose radiotherapy alone or in combination with cetuximab.
- Parotidectomy: ten-year review of 237 cases at a single institution.
- Insulin-like growth factor-I receptor signaling blockade combined with radiation.
- Planned postradiotherapy neck dissection: Rationale and clinical outcomes.
- Strategic plans to promote head and neck cancer translational research within the radiation therapy oncology group: a report from the translational research program.
- Bridging gaps in multidisciplinary head and neck cancer care: nursing coordination and case management.
- The 2007 Inaugural ASTRO/ASCO/AHNS Multidisciplinary Head and Neck Cancer Symposium.
- Stepwise progress in epidermal growth factor receptor/radiation studies for head and neck cancer.
- Clinical implementation of adaptive helical tomotherapy: a unique approach to image-guided intensity modulated radiotherapy.
- Impact of conventional radiotherapy on health-related quality of life and critical functions of the head and neck.
- Augmentation of radiation response with the vascular targeting agent ZD6126.
- Anti-EGFR therapy update: clinical experience and adverse event insights.
- Enhancing the antitumor activity of ErbB blockade with histone deacetylase (HDAC) inhibition.
- Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck.
- Biologic basis for combining drugs with radiation.
- Radiation combined with EGFR signal inhibitors: head and neck cancer focus.
- Radiation and new molecular agents, part II: targeting HDAC, HSP90, IGF-1R, PI3K, and Ras.
- Clinical advancement of EGFR inhibitors in cancer therapy.
- Parotid area lymph node metastases from cutaneous squamous cell carcinoma: implications for diagnosis, treatment, and prognosis.
- Angiogenesis and radiation response modulation after vascular endothelial growth factor receptor-2 (VEGFR2) blockade.
- Intensity-modulated radiation therapy in the management of head and neck cancer.
- Modulation of radiation response by histone deacetylase inhibition.
- Mechanisms of enhanced radiation response following epidermal growth factor receptor signaling inhibition by erlotinib (Tarceva).
- Precautions in the use of intensity-modulated radiation therapy.
- The impact of daily setup variations on head-and-neck intensity-modulated radiation therapy.
- Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor.
- Combining EGFR inhibitors with radiation or chemotherapy: will preclinical studies predict clinical results?
- Searching for reliable epidermal growth factor receptor response predictors: commentary re M. K. Nyati et al., Radiosensitization by pan-ErbB inhibitor CI-1033 in vitr...
- Chemoradiation for upper aerodigestive tract cancer: balancing evidence from clinical trials with individual patient recommendations.
- Clinical promise tempered by reality in the delivery of combined chemoradiation for common solid tumors.
- Modulation of radiation response and tumor-induced angiogenesis after epidermal growth factor receptor inhibition by ZD1839 (Iressa).
- Helical tomotherapy: an innovative technology and approach to radiation therapy.
- Epidermal growth factor receptor modulation of radiation response: preclinical and clinical development.
- Molecular inhibition of angiogenesis and metastatic potential in human squamous cell carcinomas after epidermal growth factor receptor blockade.
- IMC-C225, an anti-epidermal growth factor receptor monoclonal antibody, for treatment of head and neck cancer.
- Monoclonal antibody blockade of the epidermal growth factor receptor in cancer therapy.
- Radiation response modification following molecular inhibition of epidermal growth factor receptor signaling.
- Multiple daily fractionation radiotherapy schedules in lung cancer.
- Head and neck cancer as a clinical model for molecular targeting of therapy: combining EGFR blockade with radiation.
- Confirmation of improved local-regional control with altered fractionation in head and neck cancer.
- Modulation of radiation response after epidermal growth factor receptor blockade in squamous cell carcinomas: inhibition of damage repair, cell cycle kinetics, and tum...
- Modulation of molecular targets to enhance radiation.
- Epidermal growth factor receptor inhibition in cancer therapy: biology, rationale and preliminary clinical results.
- Modulation of tumor cell proliferation and apoptosis by polyamine depletion in cells of head and neck squamous cell carcinomas.
- Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck.
- Improving dose homogeneity in routine head and neck radiotherapy with custom 3-D compensation.
- Influence of computed tomography on pretherapeutic tumor staging in head and neck cancer patients.
- Re: Distinguishing second primary tumors from lung metastases in patients with head and neck squamous cell carcinoma.
- Antiproliferative effects of N1,N4-dibenzylputrescine in human and rodent tumor cells.
- Planned postradiotherapy neck dissection in patients with advanced head and neck cancer.
- Mucoepidermoid carcinoma in a 10-year-old girl.
- Why has induction chemotherapy for advanced head and neck cancer become a United States community standard of practice?
- Growth inhibition of squamous cell carcinoma xenografts with the polyamine analogue BE 4444.
- Manpower issues and training program directions in radiation oncology.
- Dose intensification in curative head and neck cancer radiotherapy--linear quadratic analysis and preliminary assessment of clinical results.
- Modulation of proliferation kinetics in human squamous cell carcinomas of the head and neck.
Schools
Univ Of Va Sch Of Med Hlth Sys
Uc Davis Med Center
University Ariz Med Center
Doctors Specialties
- Radiation Oncology
Accepted Insurances
- Choice Plus POS II
- Anthem Blue Cross Blue Shield HMO
- Anthem Blue Cross Blue Shield PPO
- Blue Preferred Plus POS
- Blue Card PPO
- Blue Cross Blue Shield of Illinois PPO
- Cigna PPO
- Great West Healthcare-Cigna PPO
- Open Access Plus
- Coventry Health Care of Illinois PPO
- Health and Life PPO
- Platinum PPO
- Coventry Health Care of Missouri PPO
- First Health (Coventry Health Care) PPO
- Health Alliance PPO
- Choice Care PPO
- Navigate HMO
Awards
- America's Top Doctors
- America's Top Doctors for Cancer
Education
-
University of Arizona -
University of California Davis -
University of Virginia School of Medicine
Hospital
-
University of Wisconsin Hospital and Clinics
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1902869522 |
| Last Name Of The Provider | HARARI |
| First Name Of The Provider | PAUL |
| View All |
Similar Doctors
|
|
William J. Magnuson
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Steven P. Howard, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Michael W. Zinda, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. John A. Flickinger, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Michelle M. MacKay, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Timothy J. Kruser, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Daniel H. Barnett, MD |
|
|
Dr. Patricia A. Barrett, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jeffrey V. Brower, MD |
|
|
Dr. Craig R. Hullett, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Pranshu Mohindra, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Patrick S. Fernandes, MB
This Doctor is OpenDoctor Recommended.
|